

**ACETYLCHOLINE RECEPTOR BINDING AB**

Status: Final result MyChart: Not Released

	Value	Range
ACETYLCHOL RECEPTOR BINDING AB	0.0	0.0 - 0.4 nmol/L

Comments:

INTERPRETIVE INFORMATION: Acetylcholine Binding Ab Negative 0.0 - 0.4 nmol/L Positive 0.5 nmol/L or greater Approximately 85-90 percent of patients with myasthenia gravis (MG) express antibodies to the acetylcholinereceptor (AChR), which can be divided into binding, blocking, and modulating antibodies. Binding antibody can activate complement and lead to loss of AChR. Blocking antibody may impair binding of acetylcholine to the receptor, leading to poor muscle contraction. Modulating antibody causes receptor endocytosis resulting in loss of AChR expression, which correlates most closely with clinical severity of disease. Approximately 10-15 percent of individuals with confirmed myasthenia gravis have no measurable binding, blocking, or modulating antibodies. Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS Performed by ARUP Laboratories, 500 Chipeta Way, SLC, UT 84108 800-522-2787 www.aruplab.com, Jerry W. Hussong, MD - Lab. Director

Resulting Agency

NEW YORK HOSPITAL LABORATORIES

Specimen Collected: 08/19/13
4:08 PMLast Resulted: 08/21/13
11:03 PM**Order Information** [Lab Collection Information](#), [Order Information](#), [Order Providers](#)



ACETYLCHOLINE RECEPTOR BLOCKING AB

Status: Final result MyChart: Not Released

Value

Range

ACETYLCHOL RECBLOCKING AB

0

0 - 15 %

Comments:

INTERPRETIVE INFORMATION: Acetylcholine Blocking Ab Negative
0-15 percent blocking Indeterminate 16-24 percent blocking Positive
..... 25 percent or greater blocking Approximately 85-90 percent of
patients with myasthenia gravis (MG) express antibodies to the
acetylcholinereceptor (AChR), which can be divided into binding, blocking, and
modulating antibodies. Binding antibody can activate complement and lead to
loss of AChR. Blocking antibody may impair binding of acetylcholine to
thereceptor, leading to poor muscle contraction. Modulating antibody causes
receptor endocytosis resulting in loss of AChR expression, which correlates
most closely with clinical severity of disease. Approximately 10-15 percent of
individuals with confirmed myasthenia gravis have no measurable binding,
blocking, or modulating antibodies. Test developed and characteristics
determined by ARUP Laboratories. See Compliance Statement B:
aruplab.com/CS Performed by ARUP Laboratories, 500 Chipeta Way, SLC, UT 84108
800-522-2787 www.aruplab.com, Jerry W. Hussong, MD - Lab. Director

Resulting Agency

NEW YORK HOSPITAL LABORATORIES

Specimen Collected: 08/19/13
4:08 PMLast Resulted: 08/21/13
11:06 PM**Order Information** Lab Collection Information, Order Information, Order Providers